Medtronic plc announced a definitive agreement to acquire Scientia Vascular, a private company headquartered in Salt Lake City, Utah, for $550 million. The transaction is expected to close in the first half of fiscal year 2027, subject to regulatory approval and customary closing conditions. The deal will add a suite of guidewires and catheters that enable simpler and faster access to complex cerebral vasculature, complementing Medtronic’s existing neurovascular portfolio.
The acquisition is positioned to accelerate innovation in neurovascular care. "Medtronic is thrilled to acquire Scientia to accelerate meaningful innovation in neurovascular care. This acquisition positions Medtronic with a full suite of products. It builds a strong foundation for Medtronic and supports procedures across both hemorrhagic and acute ischemic stroke. Medtronic's best‑in‑class therapies, combined with Scientia's leading access portfolio, will be incredibly powerful," said Linnea Burman, senior vice president and president of Medtronic’s Neurovascular business.
Financially, the purchase is projected to be minimally dilutive to Medtronic’s adjusted earnings per share in fiscal year 2027 and accretive thereafter. The deal may include undisclosed earn‑out and milestone payments. Medtronic’s recent performance provides context: in Q3 FY2026, the company reported revenue of $9.0 billion, up 8.7% as reported and 6.0% organically, with a non‑GAAP diluted EPS of $1.36. The company reiterated its FY2026 organic revenue growth guidance of approximately 5.5% and EPS guidance of $5.62 to $5.66.
Management emphasized the strength of the company’s portfolio and confidence in long‑term growth. "Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance, demonstrating the strength of our portfolio. By unlocking new markets and investing in high‑growth opportunities, we are accelerating performance across the company. Our innovation pipeline and portfolio breadth give us confidence in our ability to sustain long‑term growth. It's an exciting time for Medtronic," said CEO Geoff Martha. Rick Randall, CEO of Scientia Vascular, added, "the deal positions Medtronic with a comprehensive portfolio and complete guidewire line."
The acquisition aligns with Medtronic’s broader strategy to expand its neurovascular offerings and to strengthen its position in a market where rapid intervention is critical. The company has also announced plans to separate its Diabetes business into a standalone public company, further underscoring its focus on high‑growth, high‑margin segments.
The transaction is expected to close in the first half of fiscal year 2027, pending regulatory approval from the relevant authorities. The deal is a significant step in Medtronic’s effort to provide a more complete procedural solution for stroke treatment and to reinforce its leadership in the neurovascular space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.